Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00200369 · ClinicalTrials.gov registry record
Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen
A clinical trial, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- 90
- Enrollment target
NCT00200369: Completed study, sponsored by Montefiore Medical Center.
NCT00200369 is a clinical trial that has completed, run by Montefiore Medical Center. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00200369 has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- 90 participants
- Enrollment target
Study Summary
The hypothesis of this study is that the level of adherence necessary to achieve HIV virologic suppression with a ritonavir boosted protease inhibitor regimen (i.e. lopinavir/ritonavir) is less than the 95% rate observed in the published literature with unboosted regimens.
Interventions
- DEVICE MEMS cap
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-03 |
What the finished NCT00200369 record still lists
NCT00200369 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 90 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which MEMS cap is the first listed.
NCT00200369 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00200369 about?
NCT00200369 is a clinical study titled "Characterization of the Adherence Threshold for HIV Suppression of a Kaletra-based Regimen". The hypothesis of this study is that the level of adherence necessary to achieve HIV virologic suppression with a ritonavir boosted protease inhibitor regimen (i.e. lopinavir/ritonavir) is less than the 95% rate observed in the published literature with unboosted regimens.
What is the current status of trial NCT00200369?
This trial is currently completed. The enrollment target is 90 participants. The study started on 2004-05. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00200369?
The interventions under investigation include: MEMS cap (DEVICE).
Who is sponsoring clinical trial NCT00200369?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia